Alnylam Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US02043Q1076

SecurityALNY / Alnylam Pharmaceuticals, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership875 shares
Latest Disclosed Value $ 285,328
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 12.06% decrease in ownership of ALNY / Alnylam Pharmaceuticals, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 875 shares of Alnylam Pharmaceuticals, Inc. (US:ALNY) valued at $285,329 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 995 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -12.06% during the quarter. The current value of the position is $265,685 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Alnylam Pharmaceuticals EC US02043Q1076 875 -120 -12.06 285 6.34 3.1710
2025-05-29 2025-03-31 NP Alnylam Pharmaceuticals EC US02043Q1076 995 -27 -2.64 269 11.67 2.8542
2025-03-03 2024-12-31 NP Alnylam Pharmaceuticals EC US02043Q1076 1,022 -85 -7.68 240 -21.05 2.4109
2024-11-29 2024-09-30 NP Alnylam Pharmaceuticals EC US02043Q1076 1,107 -332 -23.07 304 -12.89 2.7576
2024-08-29 2024-06-30 NP Alnylam Pharmaceuticals EC US02043Q1076 1,439 -283 -16.43 350 35.80 3.1879
2024-05-30 2024-03-31 NP Alnylam Pharmaceuticals EC US02043Q1076 1,722 237 15.96 257 -9.51 2.1825
2024-02-29 2023-12-31 NP Alnylam Pharmaceuticals EC US02043Q1076 1,485 66 4.65 284 13.15 2.3297
2023-11-29 2023-09-30 NP Alnylam Pharmaceuticals EC US02043Q1076 1,419 -209 -12.84 251 -18.77 2.1759
2023-08-28 2023-06-30 NP Alnylam Pharmaceuticals EC US02043Q1076 1,628 -52 -3.10 309 -8.04 2.4402
2023-05-30 2023-03-31 NP Alnylam Pharmaceuticals EC US02043Q1076 1,680 -206 -10.92 337 -25.00 2.5490
2023-02-28 2022-12-31 NP Alnylam Pharmaceuticals EC US02043Q1076 1,886 102 5.72 448 25.49 2.7105
2022-11-29 2022-09-30 NP Alnylam Pharmaceuticals EC US02043Q1076 1,784 -383 -17.67 357 12.97 2.4920
2022-08-29 2022-06-30 NP Alnylam Pharmaceuticals EC US02043Q1076 2,167 -90 -3.99 316 -14.13 2.1683
2022-05-26 2022-03-31 NP Alnylam Pharmaceuticals EC US02043Q1076 2,257 -259 -10.29 369 -13.62 2.1778
2022-02-28 2021-12-31 NP Alnylam Pharmaceuticals EC US02043Q1076 2,516 232 10.16 427 -1.16 1.8854
2021-11-29 2021-09-30 NP Alnylam Pharmaceuticals EC US02043Q1076 2,284 -194 -7.83 431 2.62 1.8128
2021-08-27 2021-06-30 NP Alnylam Pharmaceuticals EC US02043Q1076 2,478 -356 -12.56 420 5.00 1.7594
2021-05-27 2021-03-31 NP Alnylam Pharmaceuticals EC US02043Q1076 2,834 -394 -12.21 400 -4.53 1.8005
2021-03-01 2020-12-31 NP Alnylam Pharmaceuticals EC US02043Q1076 3,228 -821 -20.28 420 -28.86 1.7086
2020-11-25 2020-09-30 NP Alnylam Pharmaceuticals EC US02043Q1076 4,049 221 5.77 590 4.06 2.4606
2020-08-27 2020-06-30 NP Alnylam Pharmaceuticals EC US02043Q1076 3,828 -129 -3.26 567 31.63 2.2849
2020-06-01 2020-03-31 NP Alnylam Pharmaceuticals EC US02043Q1076 3,957 -252 -5.99 431 -11.16 2.6364
2020-03-02 2019-12-31 NP Alnylam Pharmaceuticals EC US02043Q1076 4,209 -530 -11.18 485 27.03 2.2438
2019-11-27 2019-09-30 NP Alnylam Pharmaceuticals EC US02043Q1076 4,739 4,739 381 2.0218
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.